Abstract:Purpose/Objective(s) Although the Lung ART study, a phase III trial, showed that postoperative radiotherapy (PORT) could not significantly improve the disease-free survival (DFS) of patients with pN2 non-small cell lung cancer (NSCLC) after complete resection. However, its subgroup analysis showed that PORT did significantly improve the DFS of those with ypN2 NSCLC after neoadjuvant therapy and surgery. Our study aimed to validate the effect of PORT on the survival of patients with ypN2 NSCLC. Materials/Methods Patients was filtrated from our center from 2004 to 2021. The inclusion criteria of patients were as follows: 1) diagnosed with NSCLC; 2) accepted neoadjuvant systematic treatments including chemotherapy, tyrosine kinase inhibitors (EGFR, ALK), or immune checkpoint inhibitors; 3) received complete resection (R0 resection); 4) with stage III ypN2 disease (AJCC 8th). We excluded patients with multiple primary malignant tumors and those who died within four months after surgery. The primary endpoint was DFS. The second endpoints were overall survival (OS) and locoregional recurrence-free survival (LRFS). Propensity-score matching (PSM) was used to match the baseline characteristics between the PORT group and the non-PORT group. Kaplan-Meier method was used to estimate the endpoints. All data were analyzed using R 4.1.2. Results Totally 185 patients were included in the final analysis. There were 49 patients (26.5%) with PORT. After 1:1 PSM between the PORT group and the non-PORT group, 82 patients remained with 41 in each group. The baseline characteristics of majority in the matched cohort were as follows: male (75.6%), smoking history (79.3%), performances scores 0-1 (100%), adenocarcinoma (47.6%), grade 3-4 (58.5%), receiving neoadjuvant chemotherapy (91.5%), lobectomy (82.9%), ypT1-2 (78.9%), and ypN2b (51.2%). The median age of patients was 58. The median numbers of examined and positive lymph nodes were 20.5 and 6. The median follow-up time was 49.5 months. The median DFS of the PORT group and the non-PORT group were 25.5 months vs. 18.6 months, with the 5-year DFS rates of 43.4% vs. 24.8%, respectively (P=0.044). The median LRFS of the two groups were not reached vs. 56.8 months, with the 5-year LRFS rates of 89.1% vs. 39.8% (P<0.001). The median OS of the two groups were not reached vs. 67.7 months, with the 5-year OS rates of 76.7% vs. 34.8% (P=0.092). Conclusion For patients with stage III ypN2 NSCLC after neoadjuvant systematic therapy followed by complete resection, PORT can significantly improve the DFS and LRFS, but failed to improve OS. However, the results need to be clarified by prospective randomized clinical trials.

Clinical Analysis of 208 Cases of Pn1 Staged Head and Neck Squamous Cell Carcinoma with or Without Neck Post-Operation Radiotherapy after High-Quality Neck Dissection: A Retrospective Cohort Study

Postoperative radiotherapy to the neck for pN1 status HNSCC patients after neck dissection

Postoperative Radiotherapy May Not Be Necessary for Locally Advanced Head and Neck Squamous Cell Carcinoma: a Case-Match Multicentre Study

Postoperative radiotherapy improves survival of patients with ypN2 non-small cell lung cancer after neoadjuvant chemotherapy followed by surgery - A propensity score matching study of the Surveillance, Epidemiology, and End Results database

Association Between Clinicopathological Factors and Postoperative Radiotherapy in Patients with Completely Resected Pathological N2 Non-Small Cell Lung Cancer.

The Management of Metastatic Neck Nodes Following Induction Chemotherapy in N2/3 Classification Hypopharyngeal Carcinoma

Survival effect of postoperative radiotherapy combined with lymph nodes examined on cavity squamous cell carcinoma patients with stage T1-2N1M0: a propensity‑adjusted SEER database analysis

The Role of Postoperative Radiotherapy on Stage N2 Non-small Cell Lung Cancer

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy

Patients with Ypn2 Non-Small Cell Lung Cancer after Neoadjuvant Chemotherapy Followed by Surgery Can Benefit from Postoperative Radiotherapy- a Retrospective Study of Surveillance, Epidemiology, and End Results Database

Postoperative Radiotherapy Can Improve the Disease-Free Survival of EGFR Wild Type Patients with Pn2 NSCLC after Complete Resection and Adjuvant Chemotherapy

P2.18-05 Patients with Ypn2 NSCLC after Neoadjuvant Chemotherapy Followed by Surgery Can Benefit from PORT – A Retrospective Study of SEER Database

The Lymph Node Status and Histologic Subtypes Influenced the Effect of Postoperative Radiotherapy on Patients with N2 Positive IIIA Non-Small Cell Lung Cancer

A multicenter retrospective analysis of patients with salivary gland carcinoma treated with postoperative radiotherapy alone or chemoradiotherapy

Postoperative Radiotherapy for Patients with Completely Resected Pathological Stage IIIA-N2 Non-Small Cell Lung Cancer: a Preferential Benefit for Squamous Cell Carcinoma

The role of postoperative radiotherapy for completely resected pIIIA-N2 non-small cell lung cancer patients with different clinicopathological features: a systemic review and meta-analysis.

Evaluation of Postoperative Radiotherapy Effect on Survival of Resected Stage III-N2 Non-small Cell Lung Cancer Patients

Postoperative concomitant chemoradiotherapy improved treatment outcomes of patients with oral cavity cancer with multiple-node metastases but no other major risk factors

Validation of the Role of Postoperative Radiotherapy in Improving Disease-Free Survival of Patients with Stage III Ypn2 Non-Small Cell Lung Cancer after Neoadjuvant Therapy Followed by Complete Resection – A Propensity-Score Matching Study

Postoperative Radiotherapy in Curatively Resected Esophageal Squamous Cell Carcinoma With Occult Recurrent Laryngeal Nerve Lymph Node Metastasis

Effect of postoperative radiotherapy on survival in patients with completely resected and pathologically confirmed stage N2 non-small-cell lung cancer: a systematic review and meta-analysis